Evidence map›Paper›PMID 25250127›Full record

ArticleIranian journal of cancer prevention2013

Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings.

Mashaallah Babashahi, Mitra Mehrazma, Seyed Javad Nasiri, Farid Azizi Jalilian, Mostafa Rezaei-Tavirani

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of cancer prevention, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. The roles of microRNAs in Wilms' tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mashaallah BabashahiDept. of Pathology, Iran University of Medical Sciences, Tehran, Iran.
Mitra MehrazmaOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Seyed Javad NasiriDept. of Pathology , Ali-Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran.
Farid Azizi JalilianDept. of Medical Microbiology, Ilam University of Medical Sciences, Ilam, Iran.
Mostafa Rezaei-TaviraniProteomics Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWilms' tumor is an emberyonal tumor arising from remnants of immature renal tissue. Her2/neu is an onco-protein which mediates cellular proliferation, differentiation and survival.

methodsIn the current study, we analyzed Her2/neu expression in 40 Wilms' tumors. The clinico-demographic data of 40 patients with Wilms' tumor were retrieved. Immunohistochemical staining for HER2/neu was performed. Her2/neuimmunoreactivity was evaluated by Canadian Consensus 2007 scoring system.

resultsAmong the 38 specimens with epithelial component, 68.5% were positive for Her2/neu, whereas there was immunoreactivity in 37% of 38 blastemal, and 12% of 31 stromal components. The Her2/neu expression was significantly higher in early stages (81.5%) than in advanced stages (36.4%) in epithelial component, but not in other components.

conclusionThis study suggested that Her2/neuexpression is associated with epithelial cell differentiation accompanied by lower stages of tumor. No significant relationship was found between Her2/neu positivity and tumor size and patient's age and gender.

Indexed as

Her2/neuNephroblastomaTumor componentWilms' tumor

Identifiers

PMID25250127
PMCPMC4142924
OpenAlexW1574745930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.